The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials

Siddharth H Sheth, Robin J Larson, Siddharth H Sheth, Robin J Larson

Abstract

Background: HIV-associated lipodystrophy syndrome (HALS) is characterized by insulin resistance, abnormal lipid metabolism and redistribution of body fat. To date, there has been no quantitative summary of the effects of insulin sensitizing-agents for the treatment of this challenging problem.

Methods: We searched MEDLINE, the Cochrane Library, clinical trial registries, conference proceedings and references for randomized trials evaluating rosiglitazone, pioglitazone or metformin in patients with evidence of HALS (last update December 2009). Two reviewers independently abstracted data and assessed quality using a standard form. We contacted authors for missing data and calculated weighted mean differences (WMD) and 95% confidence intervals (CI) for each outcome.

Results: Sixteen trials involving 920 patients met inclusion criteria. Rosiglitazone modestly improved fasting insulin (WMD -3.67 mU/L; CI -7.03, -0.31) but worsened triglycerides (WMD 32.5 mg/dL; CI 1.93, 63.1), LDL (WMD 11.33 mg/dL; CI 1.85, 20.82) and HDL (WMD -2.91 mg/dL; CI -4.56, -1.26) when compared to placebo or no treatment in seven trials. Conversely, pioglitazone had no impact on fasting insulin, triglycerides or LDL but improved HDL (WMD 7.60 mg/dL; CI 0.20, 15.0) when compared to placebo in two trials. Neither drug favorably impacted measures of fat redistribution. Based on six trials with placebo or no treatment controls, metformin reduced fasting insulin (WMD -8.94 mU/L; CI -13.0, -4.90), triglycerides (WMD -42.87 mg/dL; CI -73.3, -12.5), body mass index (WMD -0.70 kg/m2; CI -1.09, -0.31) and waist-to-hip ratio (WMD -0.02; CI -0.03, 0.00). Three trials directly compared metformin to rosiglitazone. While effects on insulin were comparable, lipid levels and measures of fat redistribution all favored metformin. Severe adverse events were uncommon in all 16 trials.

Conclusion: Based on our meta-analysis, rosiglitazone should not be used in HALS. While pioglitazone may be safer, any benefits appear small. Metformin was the only insulin-sensitizer to demonstrate beneficial effects on all three components of HALS.

Figures

Figure 1
Figure 1
Effects of insulin sensitizing drugs versus placebo or no treatment on fasting insulin and glucose levels in patients with HIV-associated lipodystrophy syndrome.
Figure 2
Figure 2
Effects of insulin sensitizing drugs versus placebo or no treatment on fasting lipids levels in patients with HIV-associated lipodystrophy syndrome.
Figure 3
Figure 3
Effects of insulin sensitizing drugs versus placebo or no treatment on body weight and morphology in patients with HIV-associated lipodystrophy syndrome.
Figure 4
Figure 4
Effects of rosiglitazone vs. metformin on insulin sensitivity, lipid profiles, and morphology in patients with HIV-associated lipodystrophy syndrome.

References

    1. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. American Journal of Medicine. 2005;118(Suppl 2):23S–28S.
    1. Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, Dupon M, Neau D, Farbos S, Marimoutou C. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clinical Infectious Diseases. 2000;31(6):1482–1487. doi: 10.1086/317477.
    1. Burgoyne R, Collins E, Wagner C, Abbey S, Halman M, Nur M, Walmsley S. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Quality of Life Research. 2005;14(4):981–990. doi: 10.1007/s11136-004-2580-2.
    1. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP, Leport C, Group AS. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15(18):2441–2444. doi: 10.1097/00002030-200112070-00012.
    1. Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, Lees RS, Schoenfeld D, Grinspoon S. Increased cardiovascular disease risk indices in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2005;39(1):44–54. doi: 10.1097/01.qai.0000159323.59250.83.
    1. Hadigan C, Meigs JB, Wilson PWF, D'Agostino RB, Davis B, Basgoz N, Sax PE, Grinspoon S. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clinical Infectious Diseases. 2003;36(7):909–916. doi: 10.1086/368185.
    1. Bergersen BM. Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs. 2006;66(15):1971–1987. doi: 10.2165/00003495-200666150-00006.
    1. The Data Collection on Adverse Events of Anti HIVDSG. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. N Engl J Med. 2003;349(21):1993–2003. doi: 10.1056/NEJMoa030218.
    1. Group DADS. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte AdA, El-Sadr W, Thiebaut R, De Wit S, Kirk O. Class of antiretroviral drugs and the risk of myocardial infarction.[see comment] New England Journal of Medicine. 2007;356(17):1723–1735. doi: 10.1056/NEJMoa062744.
    1. Grinspoon S, Carr A. Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. New England Journal of Medicine. 2005;352(1):48. doi: 10.1056/NEJMra041811.
    1. Hansen BR, Haugaard SB, Iversen J, Nielsen JO, Andersen O. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scandinavian Journal of Infectious Diseases. 2004;36(4):244–253. doi: 10.1080/00365540410019381.
    1. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.[see comment] JAMA. 2002;288(2):207–215. doi: 10.1001/jama.288.2.207.
    1. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20(16):2043–2050. doi: 10.1097/01.aids.0000247574.33998.03.
    1. Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. International Journal of Clinical Practice. 2007;61(6):999–1014. doi: 10.1111/j.1742-1241.2007.01385.x.
    1. Drechsler H, Powderly WG. Switching Effective Antiretroviral Therapy: A Review. Clinical Infectious Diseases. 2002;35(10):1219–1230. doi: 10.1086/343050.
    1. Deeks ED, Keam SJ. Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2007;67(18):2747–2779. doi: 10.2165/00003495-200767180-00008.
    1. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. The American Journal of Medicine. 2001;111(1):10–17. doi: 10.1016/S0002-9343(01)00713-6.
    1. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. Diabetes Prevention Program Research G. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.[see comment][summary for patients in Ann Intern Med. 2005 Apr 19;142(8):I46; PMID: 15838061] Annals of Internal Medicine. 2005;142(8):611–619.
    1. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–579. doi: 10.1056/NEJM199602293340906.
    1. Golay A. Metformin and body weight. International Journal of Obesity. 2008;32(1):61–72. doi: 10.1038/sj.ijo.0803695.
    1. Diehl LA, Fabris BA, Barbosa DS, De Faria EC, Wiechmann SL, Carrilho AJF. Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy. AIDS Patient Care & Stds. 2008;22(10):779–786.
    1. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. Am Soc Clin Investig. 2000;106:1305–1307. doi: 10.1172/JCI11705.
    1. Hadigan C. Peroxisome proliferator-activated receptor gamma agonists and the treatment of HIV-associated lipoatrophy: unraveling the molecular mechanism of their shortcomings. Journal of Infectious Diseases. 2008;198(12):1729–1731. doi: 10.1086/593180.
    1. Arioglu E, Duncan-Morin J, Sebring N. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Annals of Internal Medicine. 2000;133(4):263–274.
    1. Benavides S, Nahata MC. Pharmacologic therapy for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2004;38(3):448–457. doi: 10.1345/aph.1D081.
    1. McGoldrick C, Leen CLS. The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review. HIV Medicine. 2007;8(6):325–334. doi: 10.1111/j.1468-1293.2007.00480.x.
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.[Erratum appears in N Engl J Med. 2007 Jul 5;357(1):100.] New England Journal of Medicine. 2007;356(24):2457–2471. doi: 10.1056/NEJMoa072761.
    1. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology. 2002;31(1):150–153. doi: 10.1093/ije/31.1.150.
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials. 1996;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4.
    1. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J. Hyperinsulinemia as an Independent Risk Factor for Ischemic Heart Disease. N Engl J Med. 1996;334(15):952–958. doi: 10.1056/NEJM199604113341504.
    1. Livingston EH, Chandalia M, Abate N. Do current body mass index criteria for obesity surgery reflect cardiovascular risk? Surgery for Obesity & Related Diseases. 2007;3(6):577–585.
    1. Seidell JC, Perusse L, Despres JP, Bouchard C. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. American Journal of Clinical Nutrition. 2001;74(3):315–321.
    1. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, vol. 5.0.1. The Cochrane Collaboration. 2008.
    1. van Wijk JPH, de Koning EJP, Cabezas MC, op't Roodt J, Joven J, Rabelink TJ, Hoepelman AI. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.[erratum appears in Ann Intern Med. 2005 Nov 1;143(9):695 Note: dosage error in text][summary for patients in Ann Intern Med. 2005 Sep 6;143(5):I38; PMID: 16144888] Annals of Internal Medicine. 2005;143(5):337–346.
    1. Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL, Schouten JT, Fielding RA, Basar MT, Grinspoon S. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 2007;21(1):47–57. doi: 10.1097/QAD.0b013e328011220e.
    1. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.[see comment] Lancet. 2004;363(9407):429–438. doi: 10.1016/S0140-6736(04)15489-5.
    1. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.[see comment] Journal of Infectious Diseases. 2007;195(12):1754–1761. doi: 10.1086/518005.
    1. Coll B, van Wijk JPH, Parra S, Castro Cabezas M, Hoepelman IM, Alonso-Villaverde C, de Koning EJP, Camps J, Ferre N, Rabelink TJ. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. European Journal of Pharmacology. 2006;544(1-3):104–110. doi: 10.1016/j.ejphar.2006.06.014.
    1. Gavrila A, Hsu W, Tsiodras S, Doweiko J, Gautam S, Martin L, Moses AC, Karchmer AW, Mantzoros CS. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clinical Infectious Diseases. 2005;40(5):745–749. doi: 10.1086/427697.
    1. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000;284(4):472–477. doi: 10.1001/jama.284.4.472.
    1. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.[see comment] Annals of Internal Medicine. 2004;140(10):786–794.
    1. Haider DG, Schindler K, Mittermayer F, Muller M, Nowotny P, Rieger A, Luger A, Ludvik B, Wolzt M. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.[erratum appears in Clin Pharmacol Ther. 2007 Apr;81(4):611] Clinical Pharmacology & Therapeutics. 2007;81(4):580–585.
    1. Kohli R, Shevitz A, Gorbach S, Wanke C. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Medicine. 2007;8(7):420–426. doi: 10.1111/j.1468-1293.2007.00488.x.
    1. Kovacic JC, Martin A, Carey D, Wand H, Mallon PWG, Feneley MP, Emery S, Cooper DA, Carr A, Investigators R. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Antiviral Therapy. 2005;10(1):135–143.
    1. Martinez E, Domingo P, Ribera E, Milinkovic A, Arroyo JA, Conget I, Perez-Cuevas JB, Casamitjana R, de Lazzari E, Bianchi L. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antiviral Therapy. 2003;8(5):403–410.
    1. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS. 1999;13(8):1000–1002. doi: 10.1097/00002030-199905280-00023.
    1. Silic A, Janez A, Tomazic J, Karner P, Vidmar L, Sharma P, Maticic M. Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. Croatian Medical Journal. 2007;48(6):791–799. doi: 10.3325/cmj.2007.6.791.
    1. Sutinen J, Hakkinen A-M, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M, Yki-Jarvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Antiviral Therapy. 2003;8(3):199–207.
    1. Tomazic J, Karner P, Vidmar L, Maticic M, Sharma PM, Janez A. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta Dermatovenerologica Alpina, Panonica et Adriatica. 2005;14(3):99–105.
    1. Yki-Jarvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P, Hamsten A. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arteriosclerosis, Thrombosis & Vascular Biology. 2003;23(4):688–694.
    1. Slama L, Lanoy E, Valantin M-A, Bastard J-P, Chermak A, Boutekatjirt A, William-Faltaos D, Billaud E, Molina J-M, Capeau J. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113) Antiviral Therapy. 2008;13(1):67–76.
    1. Blumer R, van der Valk M, Achermans M, Endert E, Serlie M, Reiss P, Sauerwein H. A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy. Am J Physiol Endocrinol Metab. 2009;297:E1097–E1104. doi: 10.1152/ajpendo.90988.2008.
    1. Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Romer V, Haider D, Pacini G, Ludvik B, Schindler K, Rieger A. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART) Hormone & Metabolic Research. 2009;41(7):573–579.
    1. Mantzoros C, Brennan A. Combination of Insulin Sensitizer and Leptin as Treatment for HAART-Inducted Metabolic Syndrome. Boston: Beth Isreal Deaconess Medical Center; 2008. identifier: NCT00362440.
    1. Lassa-Claxton S, Cade T, Yarasheski K. Myocardial Function and FFA Metabolism in HIV Metabolic Syndrome. St. Louis: Washington University School of Medicine; 2010. identifier: NCT00656851.
    1. Lassa-Claxton S, Laciny E, Yarasheski K. Exercise and Pioglitazone for HIV-Metabolic Syndromes. St. Louis: National Institute of Diabetes and Digestions; 2009. identifier: NCT00639457.
    1. Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antiviral Therapy. 2003;8(4):347–354.
    1. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. Journal of Clinical Endocrinology & Metabolism. 2002;87(10):4611–4615.
    1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203. doi: 10.2337/dc08-9025.
    1. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE, Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.[see comment] American Journal of Medicine. 2008;121(2):149–157. doi: 10.1016/j.amjmed.2007.09.016. e142.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel